Kronos Bio, Inc.

As of May 10, 2023, Kronos Bio, Inc. is considered risky and overvalued due to its negative return on equity and poor performance compared to peers, with a one-year return of -15.38% versus the S&P 500's 17.14%.

As of May 10, 2023, Kronos Bio, Inc. is classified as risky but appears undervalued with a Price to Book Value of 0.67 and an EV to EBITDA ratio of 0.88, despite a negative Return on Equity of -56.07%, while its P/E ratio of -1.2058 is better than peers, and it has underperformed the S&P 500 with a return of -15.38% over the past year.

As of June 3, 2025, Kronos Bio, Inc. is in a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators show mixed signals, and the stock has underperformed against the S&P 500 year-to-date and over the past year.

As of March 2022, the management team of Kronos Bio, Inc. includes Dr. Arie Belldegrun as Chairman of the Board and Dr. Norbert Bischofberger as President, CEO, and Director.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics targeting dysregulated transcription, with a market capitalization of approximately $53.96 million. As of March 2025, it reported net sales of $2 million and a net loss of $8 million.

As of Jun 18, Kronos Bio, Inc. has a market capitalization of 53.96 million and reported net sales of 9.19 million with a net profit of -64.48 million over the last four quarters. Shareholder's funds are 87.58 million, and total assets are 124.55 million.